Rockwell Medical (NASDAQ:RMTI) Given New $7.00 Price Target at HC Wainwright

Rockwell Medical (NASDAQ:RMTI) had its price target reduced by HC Wainwright from $9.00 to $7.00 in a research report released on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2024 earnings at $0.02 EPS, FY2024 earnings at $0.03 EPS, Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.01 EPS and FY2025 earnings at ($0.03) EPS.

A number of other equities research analysts have also recently commented on RMTI. StockNews.com cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Rodman & Renshaw began coverage on shares of Rockwell Medical in a research report on Thursday, November 14th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a research note on Thursday, November 14th.

Rockwell Medical Trading Down 1.3 %

Shares of RMTI stock opened at $2.22 on Monday. The business’s fifty day moving average price is $3.43 and its 200 day moving average price is $2.66. The firm has a market capitalization of $71.75 million, a PE ratio of -44.40 and a beta of 1.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.41 and a quick ratio of 2.00. Rockwell Medical has a 1-year low of $1.16 and a 1-year high of $5.15.

Institutional Trading of Rockwell Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC grew its stake in Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after buying an additional 592,000 shares during the period. Vanguard Group Inc. raised its stake in shares of Rockwell Medical by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after acquiring an additional 43,302 shares during the period. Jane Street Group LLC acquired a new position in shares of Rockwell Medical during the 3rd quarter valued at $534,000. Walleye Capital LLC purchased a new stake in Rockwell Medical during the 3rd quarter worth $435,000. Finally, Renaissance Technologies LLC increased its holdings in Rockwell Medical by 877.1% in the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after purchasing an additional 92,189 shares in the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.